GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Acurx Pharmaceuticals
Acurx Pharmaceuticals is a biotech company developing a new class of antibiotics. Its stock price represents a venture bet on a breakthrough in the fight against drug-resistant bacteria. The chart reflects the binary risks of clinical trials.
Share prices of companies in the market segment - Pharma microbes
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat bacterial infections resistant to existing drugs. We've classified it in the Pharma: Microbes category. The chart below shows how investors value companies solving the problem of antibiotic resistance.
Broad Market Index - GURU.Markets
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat resistant bacterial infections. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ACXP - Daily change in the company's share price Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc.'s daily price change reflects the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its new class of antibiotics.
Daily change in the price of a set of shares in a market segment - Pharma microbes
Acurx Pharmaceuticals is tackling the growing threat of superbugs by developing a new generation of antibiotics. This segment of biotech is highly volatile, as success depends on the outcome of clinical trials. The chart below shows the average daily volatility in this industry, which can help assess whether ACXP's fluctuations are typical for the sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Acurx Pharmaceuticals is a pharmaceutical company specializing in infectious diseases. Its shares are driven by news about the development of new antibiotics. This dynamic, specific to the pharmaceutical industry, creates fluctuations that contribute to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Acurx Pharmaceuticals
Acurx Pharmaceuticals' year-to-date performance is a story about the development of a new class of antibiotics. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead candidate for the treatment of C. difficile infection could offer a new mechanism of action to combat the growing threat of antibiotic resistance.
Annual dynamics of market capitalization of the market segment - Pharma microbes
As an early-stage biotech, Acurx is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its antibiotics. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Acurx Pharmaceuticals, a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria, is solving one of the most pressing global health challenges. Its year-over-year market capitalization reflects the urgency of this challenge and the expectations for its clinical candidates.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Acurx Pharmaceuticals
Acurx is a biopharmaceutical company fighting antibiotic-resistant bacteria. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its antibiotics is a binary outcome event for its stock.
Monthly dynamics of market capitalization of the market segment - Pharma microbes
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacterial infections such as C. difficile. The pharmaceutical sector's pipeline reflects the urgent need for new antibiotics, which provides an important backdrop for assessing the potential of Acurx's developments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Acurx Pharmaceuticals is developing a new class of antibiotics to combat resistant bacteria. This is a critically important area of medicine. The company's stock price is not dependent on the market, but rather on clinical trial results. Success could lead to explosive growth, as antibiotic resistance is a pressing issue.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Acurx Pharmaceuticals
Acurx Pharmaceuticals, a biotech company developing a new class of antibiotics, is tackling the global problem of drug resistance. Its weekly stock price is a direct response to clinical trial results that could offer a solution to one of medicine's most pressing problems.
Weekly dynamics of market capitalization of the market segment - Pharma microbes
Acurx Pharmaceuticals is developing a new class of antibiotics to combat drug-resistant bacteria. This is a critically important but complex area for the pharmaceutical industry. The chart below shows how investors view its progress and how its performance compares to other biotech companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Acurx Pharmaceuticals is developing new antibiotics. Its future depends on the success of clinical trials. The chart clearly shows how its shares operate in a world of their own, where a single piece of news can cause huge swings, ignoring the market.
Market capitalization of the company, segment and market as a whole
ACXP - Market capitalization of the company Acurx Pharmaceuticals
Acurx Pharmaceuticals' market capitalization reflects investors' bets on its new class of antibiotics. The chart demonstrates the market's belief that its drugs will combat bacterial infections resistant to existing drugs. Its low price reflects both the enormous need for new antibiotics and the historical difficulties with their commercialization.
ACXP - Share of the company's market capitalization Acurx Pharmaceuticals within the market segment - Pharma microbes
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. Its market share is small, but it is solving one of the most pressing healthcare problems. Its market cap is a bet on its scientific approach in an era of growing antibiotic resistance.
Market capitalization of the market segment - Pharma microbes
This chart shows the overall market capitalization of the entire pharmaceutical sector focused on fighting microbes. For Acurx, which is developing a new generation of antibiotics, this line represents a global threat. The rising chart reflects the growing problem of antibiotic resistance and the urgent need for new drugs to combat superbugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Acurx Pharmaceuticals is developing a new class of antibiotics to combat drug-resistant bacteria. Its market capitalization reflects its commitment to combating one of the major threats to global health. This represents the market share of the company's research into weapons against superbugs.
Book value capitalization of the company, segment and market as a whole
ACXP - Book value capitalization of the company Acurx Pharmaceuticals
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics. Its book value is its financial resources for research. It consists of cash that allows it to conduct clinical trials. How has this capital changed in the fight against superbugs? The chart below shows.
ACXP - Share of the company's book capitalization Acurx Pharmaceuticals within the market segment - Pharma microbes
Acurx Pharmaceuticals is a biotech company fighting antibiotic-resistant bacteria. Its research and development activities require a resource base: a laboratory for developing and testing new antibacterial drugs. The chart shows the company's share of the physical R&D infrastructure for this critical segment.
Market segment balance sheet capitalization - Pharma microbes
Acurx Pharmaceuticals is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Acurx focuses on antibiotic development, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Acurx Pharmaceuticals' assets are not factories, but capital invested in clinical trials of a new class of antibiotics to combat bacterial infections resistant to existing drugs. These assets reflect its financial resources to address this global health problem.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Acurx Pharmaceuticals
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics. Its market capitalization is an estimate of its chances of success in the fight against the growing problem of antibiotic resistance.
Market to book capitalization ratio in a market segment - Pharma microbes
Acurx Pharmaceuticals is a biotech company developing a new class of antibiotics. This is a critically important but complex area. The chart shows how investors assess its chances of success in the fight against bacterial drug resistance, a global problem.
Market to book capitalization ratio for the market as a whole
Acurx Pharmaceuticals is battling antibiotic-resistant bacteria. The company's market value reflects the potential of its developments to address one of the most pressing global health challenges. This chart shows how much investors are willing to invest in research aimed at combating global threats.
Debts of the company, segment and market as a whole
ACXP - Company debts Acurx Pharmaceuticals
Acurx, a clinical-stage biopharmaceutical company developing a new class of antibiotics, is funding its research with raised capital. This chart shows the financial needs of a company tackling a complex scientific challenge in a field where many major players have failed.
Market segment debts - Pharma microbes
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics to combat drug-resistant bacteria. This is a critically important but complex area. The chart shows how the company is funding its expensive clinical trials in hopes of providing a solution to one of the most serious threats to global health.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Acurx Pharmaceuticals
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. Clinical trials of new antibiotics are a long and risky process. This chart shows how the company uses debt to fund its vital but expensive research.
Market segment debt to market segment book capitalization - Pharma microbes
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. This is a critically important but complex area. This chart shows how the company is funding its clinical trials, comparing its debt structure to the overall financial picture in the biotech sector.
Debt to book value of all companies in the market
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. This is a critically important but complex area. How dependent is the company on debt for its research? This chart of total debt in the economy provides context for assessing its financial strategy.
P/E of the company, segment and market as a whole
P/E - Acurx Pharmaceuticals
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat resistant bacterial infections. This chart shows how investors view the company in light of the global problem of antibiotic resistance.
P/E of the market segment - Pharma microbes
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics for the treatment of infections caused by resistant bacteria. This chart illustrates the average valuation in the pharmaceutical sector, where there is a significant need for new antibiotics, but their development is associated with high risks.
P/E of the market as a whole
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics to treat infections caused by drug-resistant bacteria. This chart reflects investors' overall risk appetite. It helps understand whether ACXP's valuation is based on faith in its scientific approach to fighting superbugs or whether it moves in line with overall biotech sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Acurx Pharmaceuticals
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat bacterial infections resistant to existing drugs. This chart reflects investor confidence in the company's ability to address one of the most pressing global health challenges and the commercial potential of its developments.
%20P%2FE%20Acurx%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Acurx-Pharmaceuticals&v=1772605018806 "Chart of the company's future (projected) P/E Acurx Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma microbes
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat infections resistant to existing drugs. The chart reflects expectations for future profits in the sector, helping to understand how highly the market perceives Acurx's chances of successfully solving one of the most pressing global health problems.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-microbes&v=1772605018885 "Future (projected) P/E graph of the market segment - Pharma microbes")
Future (projected) P/E of the market as a whole
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. Antibiotic resistance is a global problem. This risk appetite chart shows whether investors are willing to fund the development of new antibiotics, which has historically been difficult to commercialize.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772605018967 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Acurx Pharmaceuticals
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. Its financial indicators reflect R&D expenditures. This chart shows investments in addressing one of the most serious threats to global health.
Profit of companies in the market segment - Pharma microbes
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria such as Clostridioides difficile. This chart shows overall profitability in the antimicrobial sector, where there is a pressing global need for new antibiotics.
Overall market profit
Acurx Pharmaceuticals is a biopharmaceutical company developing new antibiotics to combat resistant bacterial infections. The need for new antibiotics is one of the most pressing healthcare challenges and is not dependent on the state of the economy. The company's success is determined by the results of clinical trials, not the dynamics shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Acurx Pharmaceuticals
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. Future profits depend on the success of clinical trials, a significant challenge for all new antibiotics. This chart shows analyst expectations for its ability to address the problem of antibiotic resistance.
%20profit%20of%20the%20company%20Acurx%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Acurx-Pharmaceuticals&v=1772605019241 "Graph of future (projected) profit of the company Acurx Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma microbes
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacterial infections, particularly Clostridioides difficile. This chart shows revenue projections for the pharmaceutical sector, helping to assess Acurx's progress in addressing the pressing problem of antibiotic resistance.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-microbes&v=1772605019268 "Graph of future (predicted) profits of companies in a market segment - Pharma microbes")
Future (predicted) profit of the market as a whole
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics. Its prospects depend on the success of clinical trials and the fight against antibiotic resistance. This economic outlook impacts the availability of funding to address long-term healthcare challenges.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772605019270 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Acurx Pharmaceuticals
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. It has no revenue yet. This chart reflects investor assessments of its potential to address the global problem of antibiotic resistance.
P/S market segment - Pharma microbes
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacterial infections, specifically Clostridioides difficile. This chart reflects the average revenue estimate for the sector, which helps understand the market's focus on superbug research and Acurx's developments.
P/S of the market as a whole
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat drug-resistant infections. This chart highlights how the valuation of such companies reflects the urgent need for new antibiotics, which can justify a high valuation even without revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Acurx Pharmaceuticals
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. Its revenue valuation is crucial, reflecting investors' expectations that its drugs will help address the growing problem of antibiotic resistance, creating a huge market for them.
%20P%2FS%20Acurx%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Acurx-Pharmaceuticals&v=1772605019517 "The graph of the company's future (projected) P/S Acurx Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma microbes
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to treat infections caused by resistant bacteria. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the company's ability to combat the growing threat of antibiotic resistance and the potential of its drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-microbes&v=1772605019588 "Future (projected) P/S market segment graph - Pharma microbes")
Future (projected) P/S of the market as a whole
Acurx Pharmaceuticals is developing a new class of antibiotics to combat bacterial infections resistant to existing drugs. The company's future depends on the success of clinical trials. This chart of overall market expectations reflects the urgent need for new antibiotics and investor confidence that solving this problem will be highly rewarding.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772605019619 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Acurx Pharmaceuticals
This figure reflects the financial performance of Acurx Pharmaceuticals, a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat resistant bacterial infections. Commercial sales revenue is not available, and financial indicators reflect clinical trial expenses.
Sales of companies in the market segment - Pharma microbes
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics to combat drug-resistant bacteria. It currently has no revenue. Its future revenue depends on the success of its innovative drugs in addressing one of the most pressing global health challenges.
Overall market sales
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat resistant bacterial infections. Antibiotic resistance is a global threat. This general economic outlook is irrelevant to a company solving one of the most pressing problems in modern healthcare.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Acurx Pharmaceuticals
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat bacterial infections resistant to existing drugs. Future revenue depends on the success of clinical trials. This chart reflects analysts' forecasts for the commercial potential of its drugs amid the growing threat of antibiotic resistance.
%20sales%20of%20the%20company%20Acurx%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Acurx-Pharmaceuticals&v=1772605019874 "Schedule of future (projected) sales of the company Acurx Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma microbes
Acurx Pharmaceuticals is developing a new class of antibiotics to combat resistant bacterial infections. This chart shows the outlook for the pharmaceutical market. The growing threat of antibiotic resistance is creating an urgent need for new drugs, which could drive growth. This reflects general expectations.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-microbes&v=1772605019995 "Schedule of future (projected) sales of companies in the market segment - Pharma microbes")
Future (projected) sales of the market as a whole
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics. The need for new antibiotics to combat drug-resistant bacteria is enormous and represents a global health challenge. This general economic activity schedule does not affect the urgency of this medical need or Acurx's scientific activities.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772605020042 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Acurx Pharmaceuticals
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat resistant bacterial infections. This chart reflects its financial performance. Profitability depends on the success of clinical trials and potential approval of its drugs, which could become important weapons in the fight against the growing threat of antibiotic resistance.
Market segment marginality - Pharma microbes
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics to combat resistant bacterial infections. This chart depicts its financial performance, with profitability dependent on clinical trial success and addressing the pressing problem of antibiotic resistance.
Market marginality as a whole
Acurx Pharmaceuticals is a biotech company developing a new class of antibiotics to combat drug-resistant bacteria. Its mission is critical to global health. This total return chart reflects the investment climate, which determines how willing the market is to fund long-term solutions to fundamental problems in medicine.
Employees in the company, segment and market as a whole
Number of employees in the company Acurx Pharmaceuticals
Acurx Pharmaceuticals is a clinical-stage biotech company developing a new class of antibiotics to combat drug-resistant bacteria. Its small staff is focused on conducting clinical trials. This graphic shows the compact team working to address one of the most pressing challenges in medicine: antibiotic resistance.
Share of the company's employees Acurx Pharmaceuticals within the market segment - Pharma microbes
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. Its team consists of microbiologists and clinical trial specialists. This chart shows the company's market share, reflecting the scale of its R&D program in a critical area of medicine.
Number of employees in the market segment - Pharma microbes
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat resistant bacterial infections. The chart reflects employment in the microbial pharmaceuticals sector. Antibiotic resistance is a global threat, and Acurx's innovative drugs are urgently needed.
Number of employees in the market as a whole
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. This is a critically important area of medicine. The company's growth is driven not by economics, but by research success. Given the overall picture in this chart, Acurx represents a sector where employment is an investment in global health security.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Acurx Pharmaceuticals (ACXP)
Acurx Pharmaceuticals is a biotech company focused on developing a new class of antibiotics to combat drug-resistant bacteria. This is a critical area of R&D. This chart shows how the market values their pipeline. It reflects the market value per employee, which is a measure of the value of their research in the fight against superbugs.
%20of%20the%20company%20Acurx%20Pharmaceuticals%20(ACXP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Acurx-Pharmaceuticals-ACXP&v=1772605020718 "Chart of market capitalization per employee (in thousands of dollars) of the company Acurx Pharmaceuticals (ACXP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma microbes
Acurx Pharmaceuticals (ACXP) is focused on developing a new class of antibiotics to combat drug-resistant bacteria. In this critical area of pharmaceuticals, this chart shows how much investors believe in their science. A high valuation per employee could indicate the company is close to developing the first new class of antibiotics in decades.
%20by%20market%20segment%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-microbes&v=1772605020803 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma microbes")
Market capitalization per employee (in thousands of dollars) for the overall market
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics. Its valuation is based on its commitment to combating the growing problem of antibiotic resistance. The chart shows a high valuation per employee, as a successful new antibiotic would be in high demand in global healthcare.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772605020857 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Acurx Pharmaceuticals (ACXP)
Acurx Pharmaceuticals is a clinical-stage biotech company developing a new class of antibiotics to combat drug-resistant bacteria. This chart shows its R&D workload. A negative figure (loss per employee) is typical for biotech, reflecting the investment in scientists and doctors to conduct expensive clinical trials.
%20Chart%20Acurx%20Pharmaceuticals%20(ACXP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Acurx-Pharmaceuticals-ACXP&v=1772605020912 "Company Profit Per Employee (in thousands of dollars) Chart Acurx Pharmaceuticals (ACXP)")
Profit per employee (in thousands of dollars) in the market segment - Pharma microbes
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat drug-resistant bacteria. Amid the antibiotic resistance crisis, the effectiveness of such a team is critical. The graph shows the financial return per employee, which is an indicator of progress in developing life-saving drugs.
%20in%20the%20market%20segment%20-%20Pharma%20microbes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-microbes&v=1772605020929 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma microbes")
Profit per employee (in thousands of dollars) for the market as a whole
Acurx Pharmaceuticals is a biotech company focused on developing a new class of antibiotics to combat drug-resistant bacteria (such as C. difficile). It's an R&D company. This chart, showing average profitability, helps clarify the contrast with biotech, where teams of scientists burn through investors' capital in hopes of drug approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772605020965 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Acurx Pharmaceuticals (ACXP)
Acurx Pharmaceuticals is a biopharmaceutical company developing new antibiotics. At the clinical stage, this figure is negligible. It reflects a huge need: a successful new antibiotic could become a lifesaving drug and generate huge revenue, leading to explosive growth in this figure.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Acurx-Pharmaceuticals-ACXP&v=1772605020989 "Sales chart per company employee Acurx Pharmaceuticals (ACXP)")
Sales per employee in the market segment - Pharma microbes
Acurx Pharmaceuticals is a clinical-stage biotech developing a new class of antibiotics to combat drug-resistant bacteria (e.g., C. difficile). They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of ACXP's R&D staffing efficiency.
Sales per employee for the market as a whole
Acurx Pharmaceuticals is a biotech company focused on developing a new class of antibiotics to combat drug-resistant bacteria. Currently, their business is focused on R&D. This chart reflects their clinical stage: the company is investing in research and has no commercial revenue yet.
Short shares by company, segment and market as a whole
Shares shorted by company Acurx Pharmaceuticals (ACXP)
Acurx (ACXP) is a biotech company developing a new class of antibiotics to combat drug-resistant bacteria. This chart tracks bearish bets. Shorts may be due to the commercial complexity of the antibiotic market (patients are taking them for a short time) or to a bet on clinical trials failing.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Acurx-Pharmaceuticals-ACXP&v=1772605021191 "Short Shares Chart for the Company Acurx Pharmaceuticals (ACXP)")
Shares shorted by market segment - Pharma microbes
Acurx Pharmaceuticals (ACXP) is a biotech company developing a new class of antibiotics to treat infections such as C. difficile. This chart aggregates short positions across the entire biotech sector. It reflects investor skepticism regarding the challenges of commercializing new antibiotics.
Shares shorted by the overall market
Acurx Pharmaceuticals is a biotech company developing new antibiotics. This chart illustrates the overall market pessimism. Despite the importance of the problem (superbugs), the antibiotic market is complex. Investors fear the R&D cycle will be long and commercialization will be difficult (hospitals are reluctant to pay for new antibiotics).
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Acurx Pharmaceuticals (ACXP)
Acurx Pharmaceuticals is working on a new line of antibiotics to combat superbugs. This is a critically important but challenging area to commercialize. This chart measures the "temperature" of clinical data. It "overheats" on news of successful phases of trials, reflecting hope for a breakthrough.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Acurx-Pharmaceuticals-ACXP&v=1772605021662 "RSI 14 indicator chart for the company's stock Acurx Pharmaceuticals (ACXP)")
RSI 14 Market Segment - Pharma microbes
Acurx (ACXP) is a biotech company developing next-generation antibiotics to combat "superbugs," particularly C. difficile. This is a critical niche. This chart tracks overall sentiment in the Pharma/Microbes sector. It helps investors understand whether ACXP's performance reflects their data or whether the overall biotech sector is overheated or oversold.
RSI 14 for the overall market
For Acurx Pharmaceuticals, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ACXP (Acurx Pharmaceuticals)
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics to combat superbugs, primarily C. difficile (CDI). This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials for this R&D pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ACXP-Acurx-Pharmaceuticals&v=1772605022150 "A chart showing analyst consensus forecasts for the expected stock price. ACXP (Acurx Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price ACXP (Acurx Pharmaceuticals)
Acurx is a biopharmaceutical company developing a *new class* of antibiotics to combat superbugs, primarily C. difficile. This chart shows how much upside or downside analysts see in the stock. It measures the gap between the price and forecast, reflecting their belief in this critically important but complex R&D market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ACXP-Acurx-Pharmaceuticals&v=1772605022270 "A chart showing the difference between the consensus forecast and the actual stock price. ACXP (Acurx Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma microbes
Acurx (ACXP) is a biotech company developing a new class of antibiotics to combat C. difficile (a severe intestinal infection) without killing "good" bacteria. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe R&D can succeed in the challenging antibiotic market.
Analysts' consensus forecast for the overall market share price
Acurx Pharmaceuticals is a biotech company developing a new class of antibiotics targeting drug-resistant bacteria (e.g., C. difficile). This chart reflects the overall risk appetite in the market. For Acurx, operating in a defensive but complex sector, overall optimism is important for funding R&D and bringing their innovative drugs to market.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Acurx Pharmaceuticals
Acurx Pharmaceuticals is a biotech R&D company waging war on superbugs. They are developing a new class of antibiotics that target DNA polymerase (not the cell wall) to treat C. difficile and other infections. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative valuation of their (very risky) pipeline.
AKIMA Market Segment Index - Pharma microbes
Acurx Pharmaceuticals (ACXP) is a biopharmaceutical company targeting superbugs. Their primary focus is treating C. difficile infections. They are developing a new class of antibiotics (ibezapolstat) that aims to kill bad bacteria without affecting good bacteria. This chart shows the average index for the segment. It helps assess how this targeted strategy compares to the industry average.
The AKIM Index for the overall market
Acurx Pharmaceuticals is a biopharmaceutical company developing a new class of antibiotics for the treatment of complex bacterial infections (C. diff). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is tackling the resistance problem, compares to overall economic trends.
